Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://f700gs.de](https://www.archivebay.com/archive6/images/daedd3d1-6518-4ca8-ac05-a6aa1750cc6a.png)
A complete backup of https://f700gs.de
Are you over 18 and want to see adult content?
![A complete backup of https://bayoubowl.org](https://www.archivebay.com/archive6/images/c6987197-fd8f-48e5-8359-8c3deff35d34.png)
A complete backup of https://bayoubowl.org
Are you over 18 and want to see adult content?
![A complete backup of https://nzlevel2seismicsurveys.co.nz](https://www.archivebay.com/archive6/images/f1def8e4-d0a4-402a-8dd8-89d1b396225e.png)
A complete backup of https://nzlevel2seismicsurveys.co.nz
Are you over 18 and want to see adult content?
![A complete backup of https://thetraveltrooper.com](https://www.archivebay.com/archive6/images/f4c246ac-4fc7-4bc5-b5cf-f7da50e6feae.png)
A complete backup of https://thetraveltrooper.com
Are you over 18 and want to see adult content?
![A complete backup of https://rockypatel.com](https://www.archivebay.com/archive6/images/0bc1aafa-4452-465c-ad8a-734719decefa.png)
A complete backup of https://rockypatel.com
Are you over 18 and want to see adult content?
![A complete backup of https://moe.org.co](https://www.archivebay.com/archive6/images/579b9e92-5066-4cbe-a30a-6403269419c5.png)
A complete backup of https://moe.org.co
Are you over 18 and want to see adult content?
![A complete backup of https://walbrofuelpumps.com](https://www.archivebay.com/archive6/images/244dad39-c074-4fc4-9ab7-c8760c7449c1.png)
A complete backup of https://walbrofuelpumps.com
Are you over 18 and want to see adult content?
![A complete backup of https://coachlevi.com](https://www.archivebay.com/archive6/images/faf1e746-c211-494e-8710-01bb9559ec9b.png)
A complete backup of https://coachlevi.com
Are you over 18 and want to see adult content?
![A complete backup of https://hochschulforumdigitalisierung.de](https://www.archivebay.com/archive6/images/dc2406fa-74b8-4e77-aa38-9fe252651d91.png)
A complete backup of https://hochschulforumdigitalisierung.de
Are you over 18 and want to see adult content?
![A complete backup of https://leftoversalmon.com](https://www.archivebay.com/archive6/images/82646732-8ec6-4a4f-a82f-22c4bb31ed4a.png)
A complete backup of https://leftoversalmon.com
Are you over 18 and want to see adult content?
![A complete backup of https://dansteinman.com](https://www.archivebay.com/archive6/images/a78aec72-e157-4122-9485-aac2d78fc8e5.png)
A complete backup of https://dansteinman.com
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of https://marathonkids.org](https://www.archivebay.com/archive6/images/b0d02967-6ee0-414f-87ec-747fcaba7de3.png)
A complete backup of https://marathonkids.org
Are you over 18 and want to see adult content?
![A complete backup of https://surfsimply.com](https://www.archivebay.com/archive6/images/d285d8be-28d0-4e9b-9a3d-22dda131c6bc.png)
A complete backup of https://surfsimply.com
Are you over 18 and want to see adult content?
![A complete backup of https://tombarefoot.com](https://www.archivebay.com/archive6/images/8e24f7ab-cd95-4408-81ed-37575956a748.png)
A complete backup of https://tombarefoot.com
Are you over 18 and want to see adult content?
![A complete backup of https://liberte-algerie.com](https://www.archivebay.com/archive6/images/b78fd25c-27fd-48f8-bd7c-d223bb7fafb8.png)
A complete backup of https://liberte-algerie.com
Are you over 18 and want to see adult content?
![A complete backup of https://gutcheckit.com](https://www.archivebay.com/archive6/images/bdec6bb7-5127-46e0-b4d9-05cf5f5a3963.png)
A complete backup of https://gutcheckit.com
Are you over 18 and want to see adult content?
![A complete backup of https://ceanational.org](https://www.archivebay.com/archive6/images/313cc8c7-e220-4b63-acae-495330c86109.png)
A complete backup of https://ceanational.org
Are you over 18 and want to see adult content?
![A complete backup of https://coautilities.com](https://www.archivebay.com/archive6/images/71542ed6-4ed8-4d1d-9daa-e58ed502e341.png)
A complete backup of https://coautilities.com
Are you over 18 and want to see adult content?
![A complete backup of https://bsonspec.org](https://www.archivebay.com/archive6/images/e3983a3b-7ff4-4d5b-b26f-160bc9c3a4d1.png)
A complete backup of https://bsonspec.org
Are you over 18 and want to see adult content?
![A complete backup of https://luckydays.com](https://www.archivebay.com/archive6/images/06ceb75b-bf28-42e5-87bc-07a81d852aab.png)
A complete backup of https://luckydays.com
Are you over 18 and want to see adult content?
![A complete backup of https://studiospares.com](https://www.archivebay.com/archive6/images/86855818-396e-493a-ad00-41bfdf490fac.png)
A complete backup of https://studiospares.com
Are you over 18 and want to see adult content?
![A complete backup of https://idealpropertycentre.co.uk](https://www.archivebay.com/archive6/images/a33ff433-2d88-4f1e-adfe-37e57c63c1ed.png)
A complete backup of https://idealpropertycentre.co.uk
Are you over 18 and want to see adult content?
![A complete backup of https://imagespaceinc.com](https://www.archivebay.com/archive6/images/b1b59827-9ba6-4fc9-a67d-246ac8ed4381.png)
A complete backup of https://imagespaceinc.com
Are you over 18 and want to see adult content?
Text
GOVERNANCE
Purpose. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions. Learn more.BDSI
BELBUCA ® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA ®) technology . Contraindications. Significant respiratorydepression.
NEWS RELEASES
April 20, 2021. BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021. PDF Version. March 10, 2021. BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results. PDF Version. February 17, 2021. BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021. PDF Version.BDSI
Being a leader means driving meaningful change. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible. Find out how you can grow with us. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. 0001103021-20-000042 BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES ANNOUNCES APPOINTMENT OF JEFF BAILEY RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionMARK A. SIRGO,
BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BDSICOMPANYPRODUCTSSCIENCE & EDUCATIONINVESTORSCAREERSCORPORATEGOVERNANCE
Purpose. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions. Learn more.BDSI
BELBUCA ® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA ®) technology . Contraindications. Significant respiratorydepression.
NEWS RELEASES
April 20, 2021. BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021. PDF Version. March 10, 2021. BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results. PDF Version. February 17, 2021. BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021. PDF Version.BDSI
Being a leader means driving meaningful change. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible. Find out how you can grow with us. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. 0001103021-20-000042 BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES ANNOUNCES APPOINTMENT OF JEFF BAILEY RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionMARK A. SIRGO,
BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDeliveryBDSI
Bailey received a Bachelor of Science Degree from Rutgers University. Mr. Plesha has served as President & Chief Commercial Officer for BDSI since he was elevated to the position in December 2017. Scott joined BDSI in August 2015, when he assumed the role of Senior Vice President of Sales & Marketing.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.BDSI
This is especially true for the more than 20 million individuals living with chronic, severe pain in the United States. At BDSI, our mission extends beyond providing access to therapeutic solutions. We believe advocating for patients—being a voice for awareness and change—is an integral part of helping individuals make progress intheir lives.
BIODELIVERY SCIENCES ANNOUNCES APPOINTMENT OF JEFF BAILEY RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020.BDSI
BDSI may use the personal data that we collect from you to operate our business. This includes complying with applicable laws, regulations, and guidance, as well as demands or requests made by regulators, courts, and lawful authorities. BDSI may use your personal data to improve our day-to-day operations such as auditing, data analysis, andSCOTT PLESHA
BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDeliveryWILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and its BIODELIVERY SCIENCES PROVIDES PIPELINE UPDATE RALEIGH, N.C., Dec. 18, 2015 / PRNewswire / -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) provided an update on its development pipeline and announced plans for an R&D day in early 2016. BDSI has initiated its multi-center, randomized, double-blind, placebo controlled study to assess the efficacy and safety of ClonidineTopical Gel
BIODELIVERY SCIENCES ANNOUNCES BELBUCA® PATENT LITIGATION RALEIGH, N.C., Feb. 06, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva BDSICOMPANYPRODUCTSSCIENCE & EDUCATIONINVESTORSCAREERSCORPORATEGOVERNANCE
BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more information on access to our products, please call our customer service line at 1-800-469-0261.BDSI
Medication Guide. BELBUCA (bel-BUE-kuh) (buprenorphine buccal film), CIII. BELBUCA is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require daily around-the-clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines or immediate-release opioid medicines do not treat your painNEWS RELEASES
The Investor Relations website contains information about BioDelivery Sciences International, Inc.'s business for stockholders, potential investors, and financial analysts. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDeliveryINVESTOR RESOURCES
BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021 April 20, 2021 RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021 BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. 0001103021-20-000042 BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 million BIODELIVERY SCIENCES ANNOUNCES APPOINTMENT OF JEFF BAILEY RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020.WILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and its BDSICOMPANYPRODUCTSSCIENCE & EDUCATIONINVESTORSCAREERSCORPORATEGOVERNANCE
BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more information on access to our products, please call our customer service line at 1-800-469-0261.BDSI
Medication Guide. BELBUCA (bel-BUE-kuh) (buprenorphine buccal film), CIII. BELBUCA is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require daily around-the-clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines or immediate-release opioid medicines do not treat your painNEWS RELEASES
The Investor Relations website contains information about BioDelivery Sciences International, Inc.'s business for stockholders, potential investors, and financial analysts. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDeliveryINVESTOR RESOURCES
BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021 April 20, 2021 RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021 BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. 0001103021-20-000042 BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 million BIODELIVERY SCIENCES ANNOUNCES APPOINTMENT OF JEFF BAILEY RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020.WILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and itsBDSI
BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more information on access to our products, please call our customer service line at 1-800-469-0261.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.NEWS RELEASES
The Investor Relations website contains information about BioDelivery Sciences International, Inc.'s business for stockholders, potential investors, and financial analysts. BIODELIVERY SCIENCES ANNOUNCES APPOINTMENT OF JEFF BAILEY RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020.SCOTT PLESHA
BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES PROVIDES PIPELINE UPDATE BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more information on access to our products, please call our customer service line at 1-800-469-0261.Q3 2020 EARNINGS
Q3 2020 Earnings Presentation I 2 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS This presentation and any statements of employees, representatives, and partners of BioDelivery Sciences International, Inc. (“BDSI”)related thereto contain, or may contain, among orthings, certain
WILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and its BIODELIVERY SCIENCES ANNOUNCES BELBUCA® PATENT LITIGATION RALEIGH, N.C., Feb. 06, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva BIODELIVERY SCIENCES RECEIVES FDA APPROVAL FOR BUNAVAIL BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more information on access to our products, please call our customer service line at 1-800-469-0261. BDSICOMPANYPRODUCTSSCIENCE & EDUCATIONINVESTORSCAREERSCORPORATEGOVERNANCE
Purpose. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions. Learn more.BDSI
BELBUCA ® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA ®) technology . Contraindications. Significant respiratorydepression.
BDSI
Being a leader means driving meaningful change. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible. Find out how you can grow with us.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.NEWS RELEASES
April 20, 2021. BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021. PDF Version. March 10, 2021. BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results. PDF Version. February 17, 2021. BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021. PDF Version. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionWILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and its BDSICOMPANYPRODUCTSSCIENCE & EDUCATIONINVESTORSCAREERSCORPORATEGOVERNANCE
Purpose. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions. Learn more.BDSI
BELBUCA ® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA ®) technology . Contraindications. Significant respiratorydepression.
BDSI
Being a leader means driving meaningful change. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible. Find out how you can grow with us.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.NEWS RELEASES
April 20, 2021. BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021. PDF Version. March 10, 2021. BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results. PDF Version. February 17, 2021. BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021. PDF Version. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionWILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and itsBDSI
Bailey received a Bachelor of Science Degree from Rutgers University. Mr. Plesha has served as President & Chief Commercial Officer for BDSI since he was elevated to the position in December 2017. Scott joined BDSI in August 2015, when he assumed the role of Senior Vice President of Sales & Marketing.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.PATIENTS FIRST
Patients First. Individuals living with serious and debilitating chronic conditions often struggle with feelings of isolation. Because the effects are often individualized to the patient, the impact can easily be misunderstood or minimized by society—leaving patients feeling abandoned and alone.BDSI
For more information on the growing BDSI portfolio, or to explore partnership opportunities, please contact Kevin Ostrander. Kevin Ostrander, SVP, Business Development 4131 Parklake Avenue, Suite 225 Raleigh, NC 27612 Tel: 919-582-9050. First Name * Last Name * Company Contact Number Email * Message Asterisks denote required fields. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionMARK A. SIRGO,
BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES ANNOUNCES BELBUCA® PATENT LITIGATION RALEIGH, N.C., Feb. 06, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva BIODELIVERY SCIENCES INTERNATIONAL, INC. ANNOUNCES PRICING RALEIGH, N.C., April 11, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced the pricing of an underwritten public offering by the Company and a selling stockholder of 12,000,000 shares of common stock at a public offering price of $5.00 per share. In addition, underwriters have a 30-day option to purchase up to an BIODELIVERY SCIENCES RECEIVES FDA APPROVAL FOR BUNAVAIL The Investor Relations website contains information about BioDelivery Sciences International, Inc.'s business for stockholders, potential investors, and financial analysts. BDSICOMPANYPRODUCTSSCIENCE & EDUCATIONINVESTORSCAREERSCORPORATEGOVERNANCE
Purpose. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions. Learn more.BDSI
BELBUCA ® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA ®) technology . Contraindications. Significant respiratorydepression.
BDSI
Being a leader means driving meaningful change. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible. Find out how you can grow with us.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.NEWS RELEASES
April 20, 2021. BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021. PDF Version. March 10, 2021. BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results. PDF Version. February 17, 2021. BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021. PDF Version. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionWILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and its BDSICOMPANYPRODUCTSSCIENCE & EDUCATIONINVESTORSCAREERSCORPORATEGOVERNANCE
Purpose. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions. Learn more.BDSI
BELBUCA ® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA ®) technology . Contraindications. Significant respiratorydepression.
BDSI
Being a leader means driving meaningful change. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible. Find out how you can grow with us.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.NEWS RELEASES
April 20, 2021. BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021. PDF Version. March 10, 2021. BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results. PDF Version. February 17, 2021. BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021. PDF Version. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionWILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and itsBDSI
Bailey received a Bachelor of Science Degree from Rutgers University. Mr. Plesha has served as President & Chief Commercial Officer for BDSI since he was elevated to the position in December 2017. Scott joined BDSI in August 2015, when he assumed the role of Senior Vice President of Sales & Marketing.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.PATIENTS FIRST
Patients First. Individuals living with serious and debilitating chronic conditions often struggle with feelings of isolation. Because the effects are often individualized to the patient, the impact can easily be misunderstood or minimized by society—leaving patients feeling abandoned and alone.BDSI
For more information on the growing BDSI portfolio, or to explore partnership opportunities, please contact Kevin Ostrander. Kevin Ostrander, SVP, Business Development 4131 Parklake Avenue, Suite 225 Raleigh, NC 27612 Tel: 919-582-9050. First Name * Last Name * Company Contact Number Email * Message Asterisks denote required fields. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionMARK A. SIRGO,
BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES ANNOUNCES BELBUCA® PATENT LITIGATION RALEIGH, N.C., Feb. 06, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva BIODELIVERY SCIENCES INTERNATIONAL, INC. ANNOUNCES PRICING RALEIGH, N.C., April 11, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced the pricing of an underwritten public offering by the Company and a selling stockholder of 12,000,000 shares of common stock at a public offering price of $5.00 per share. In addition, underwriters have a 30-day option to purchase up to an BIODELIVERY SCIENCES RECEIVES FDA APPROVAL FOR BUNAVAIL The Investor Relations website contains information about BioDelivery Sciences International, Inc.'s business for stockholders, potential investors, and financial analysts. BDSICOMPANYPRODUCTSSCIENCE & EDUCATIONINVESTORSCAREERSCORPORATEGOVERNANCE
Purpose. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions. Learn more.BDSI
BELBUCA ® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA ®) technology . Contraindications. Significant respiratorydepression.
BDSI
Being a leader means driving meaningful change. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible. Find out how you can grow with us.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.NEWS RELEASES
April 20, 2021. BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021. PDF Version. March 10, 2021. BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results. PDF Version. February 17, 2021. BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021. PDF Version. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionWILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and its BDSICOMPANYPRODUCTSSCIENCE & EDUCATIONINVESTORSCAREERSCORPORATEGOVERNANCE
Purpose. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions. Learn more.BDSI
BELBUCA ® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA ®) technology . Contraindications. Significant respiratorydepression.
BDSI
Being a leader means driving meaningful change. BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible. Find out how you can grow with us.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.NEWS RELEASES
April 20, 2021. BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021. PDF Version. March 10, 2021. BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results. PDF Version. February 17, 2021. BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021. PDF Version. FINANCIALS & FILINGS BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES CFO TERRY COELHO PROMOTED TO Brings Track Record of Success to Expanded Role. RALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionWILLIAM MARK WATSON
William Mark Watson, CPA joined our Board of Directors as an independent member in December 2017 and is Chairman of the Audit Committee. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and itsBDSI
Bailey received a Bachelor of Science Degree from Rutgers University. Mr. Plesha has served as President & Chief Commercial Officer for BDSI since he was elevated to the position in December 2017. Scott joined BDSI in August 2015, when he assumed the role of Senior Vice President of Sales & Marketing.BDSI
Medical Education Grants. BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.BDSI
April 20, 2021. RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021. Read more.PATIENTS FIRST
Patients First. Individuals living with serious and debilitating chronic conditions often struggle with feelings of isolation. Because the effects are often individualized to the patient, the impact can easily be misunderstood or minimized by society—leaving patients feeling abandoned and alone.BDSI
For more information on the growing BDSI portfolio, or to explore partnership opportunities, please contact Kevin Ostrander. Kevin Ostrander, SVP, Business Development 4131 Parklake Avenue, Suite 225 Raleigh, NC 27612 Tel: 919-582-9050. First Name * Last Name * Company Contact Number Email * Message Asterisks denote required fields. BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO Long-term revenue potential of over $75 million for NME with IP protection through 2031. Leverages existing commercial capabilities to provide a novel treatment option for OIC Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million. Long-term potential of BELBUCA ® and Symproic ® combined Net Sales expected to be $325-$400 millionMARK A. SIRGO,
BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021 Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery BIODELIVERY SCIENCES ANNOUNCES BELBUCA® PATENT LITIGATION RALEIGH, N.C., Feb. 06, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva BIODELIVERY SCIENCES INTERNATIONAL, INC. ANNOUNCES PRICING RALEIGH, N.C., April 11, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced the pricing of an underwritten public offering by the Company and a selling stockholder of 12,000,000 shares of common stock at a public offering price of $5.00 per share. In addition, underwriters have a 30-day option to purchase up to an BIODELIVERY SCIENCES RECEIVES FDA APPROVAL FOR BUNAVAIL The Investor Relations website contains information about BioDelivery Sciences International, Inc.'s business for stockholders, potential investors, and financial analysts.COVID-19 UPDATE
* Contact
* __
BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more information on access to our products, please call our customer service line at 1-800-469-0261 . We are proud to be recognized on the Deloitte 2020 Technology Fast500 list
* Company
* About BDSI
* Who We Are
* Patients First
* Products
* Products
* Technology
* Partnerships
* Science & Education* Investors
* News Releases
* Events & Presentations * Corporate Governance & Compliance * Committee Composition* Stock Information
* Financials & Filings* Analyst Coverage
* Investor Resources* Careers
* __
* Company
* About BDSI
* Who We Are
* Patients First
* Products
* Products
* Technology
* Partnerships
* Science & Education* Investors
* News Releases
* Events & Presentations * Corporate Governance & Compliance * Committee Composition* Stock Information
* Financials & Filings* Analyst Coverage
* Investor Resources* Careers
* __
We are proud to be recognized on the Deloitte 2020 Technology Fast500 list
INSPIRING SOLUTIONS FOR BETTER HEALTH BDSI advances novel therapies designed to improve the lives of people living with serious and debilitating chronic conditions THOMAS SMITH, MD, CHIEF MEDICAL OFFICER AT BDSI, INTERVIEWS HEALTHCARE EXPERTS ON WHAT PATIENTS LIVING WITH CHRONIC PAIN EXPERIENCE. Listening to healthcare practitioners helps us understand how we can deliver meaningful solutions to the patient community. We are dedicated to the constant pursuit of improving patients’ lives.Watch now
PURPOSE
BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronicconditions.
Learn more
PATIENTS
BDSI subscribes to a _patients-first_ philosophy. We are a dynamic team driven by the knowledge that the work we do can have a positive impact on patients, their caretakers, and loved ones.Learn more
PRODUCTS
BDSI offers a diverse portfolio of solutions for the treatment of serious and debilitating chronic conditions, including unique therapeutic innovations like a buccal film technology designed to help optimize drug delivery.Learn more
RECENT BDSI NEWS
May 6, 2021
Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDeliveryRead more
April 20, 2021
RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021Read more
March 10, 2021
Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST TodayRead more
More news
UPCOMING EVENTS
There are no events to displayMore events
STAY CONNECTED
Stay up to date on the latest newsGet started now
June 4, 2021BDSI $3.6/ - 0% Data provided by Nasdaq. Minimum 15 minutes delayed.Site Links
COMPANY
* About BDSI
* Who We Are
* Patients First
PRODUCTS
* Products
* Technology
* Partnerships
SCIENCE & EDUCATION
INVESTORS
* News Releases
* Events & Presentations * Corporate Governance * Committee Composition* Stock Information
* Financials & Filings* Analyst Coverage
* Investor Resources* CAREERS
* CONTACT
* STAY CONNECTED
* Company
* About BDSI
* Who We Are
* Patients First
* Products
* Products
* Technology
* Partnerships
* Science & Education* Investors
* News Releases
* Events & Presentations * Corporate Governance & Compliance * Committee Composition* Stock Information
* Financials & Filings* Analyst Coverage
* Investor Resources* Careers
Copyright © 2021 | BioDelivery Sciences International, Inc. Terms & Conditions | Privacy PolicyDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0